Overview

A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.
Details
Lead Sponsor:
Chinese PLA General Hospital
Collaborator:
LinkDoc Technology (Beijing) Co. Ltd.
Treatments:
Antibodies
Immunoglobulins